Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Graft RejectionKidney TransplantRenal Allograft RecipientsRenal Transplant
Interventions
DRUG

Tacrolimus

During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).

DRUG

Sirolimus

Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).

DRUG

Tacrolimus

During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.

Trial Locations (44)

2031

Pfizer Investigational Site, Randwick

5000

Pfizer Investigational Site, Adelaide

6009

Pfizer Investigational Site, Nedlands

10032

Pfizer Investigational Site, New York

10117

Pfizer Investigational Site, Berlin

14642

Pfizer Investigational Site, Rochester

19107

Pfizer Investigational Site, Philadelphia

20132

Pfizer Investigational Site, Milan

20162

Pfizer Investigational Site, Milan

22901

Pfizer Investigational Site, Charlottesville

22908

Pfizer Investigational Site, Charlottesville

23298

Pfizer Investigational Site, Richmond

27705

Pfizer Investigational Site, Durham

28040

Pfizer Investigational Site, Madrid

28041

Pfizer Investigational Site, Madrid

29425

Pfizer Investigational Site, Charleston

30309

Pfizer Investigational Site, Atlanta

39008

Pfizer Investigational Site, Santander

40536

Pfizer Investigational Site, Lexington

44106

Pfizer Investigational Site, Cleveland

46026

Pfizer Investigational Site, Valencia

48202

Pfizer Investigational Site, Detroit

48236

Pfizer Investigational Site, Detroit

60611

Pfizer Investigational Site, Chicago

77030

Pfizer Investigational Site, Houston

80045

Pfizer Investigational Site, Aurora

80230

Pfizer Investigational Site, Denver

92037

Pfizer Investigational Site, La Jolla

94115

Pfizer Investigational Site, San Francisco

97239

Pfizer Investigational Site, Portland

04102

Pfizer Investigational Site, Portland

02215

Pfizer Investigational Site, Boston

27599 7155

Pfizer Investigational Site, Chapel Hill

45267-0589

Pfizer Investigational Site, Cincinnati

45267-0595

Pfizer Investigational Site, Cincinnati

C1425APQ

Pfizer Investigational Site, Ciudad de Buenos Aires

90035-074

Pfizer Investigational Site, Porto Alegre

01323-030

Pfizer Investigational Site, Bela Vista

01323-000

Pfizer Investigational Site, São Paulo

01323-001

Pfizer Investigational Site, São Paulo

04038-002

Pfizer Investigational Site, São Paulo

04039-033

Pfizer Investigational Site, São Paulo

08036

Pfizer Investigational Site, Barcelona

08907

Pfizer Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY